The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1455
A Combination of Ledipasvir and Sofosbuvir (Harvoni) for Hepatitis C
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a fixed-dose combination (Harvoni [har voe' nee] – Gilead) of sofosbuvir and ledipasvir (led' i pas' vir), two oral direct-acting antiviral agents, for treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Genotype 1 is responsible for 70-80% of HCV infections in the US. Sofosbuvir (Sovaldi) was approved earlier for use in combination with other antiviral drugs for treatment of HCV infection. Ledipasvir is a new drug.

DRUGS FOR HCV INFECTION — Sofosbuvir is the most effective drug available to date for treatment of chronic HCV infection, and it appears to have a high genetic barrier to resistance.1 In combination with pegylated interferon and/or ribavirin, or with the protease inhibitor simeprevir (Olysio),2 sofosbuvir has produced higher sustained virologic response (SVR) rates ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Combination of Ledipasvir and Sofosbuvir (Harvoni) for Hepatitis C
Article code: 1455b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian